Hillary Clinton accused Pfizer of using legal loopholes to avoid its "fair share" of taxes.» Read More
Pfizer Chairman and CEO Jeff Kindler last year repeatedly said big deals in big pharma don't work. But, he added, he'd never say never. And sure enough, this year Kindler's buying Wyeth.
This takes the prize for the most dangerously optimistic acronym for a clinical trial. But MADIT (pronounced "made it") made it. Some folks with a lot of chutzpah at Guidant, now owned by Boston Scientific, apparently came up with the name for their big studies on implantable cardio defibrillators.
Stocks rose on Thursday, snapping a two-day losing streak, as investors gave techs another go and Wal-Mart hit its earnings target. However, some economic reports that missed expectations curbed gains. Experts weighed in on the markets, the commercial real estate, and more...
Stocks lost more than 2% Wednesday as bank shares continued to struggle and retail sales unexpectedly fell for a second straight month.
A gloomy sales report dragged down investor sentiment on Wednesday sending the S&P 500 to its third straight day of declines.
Stocks declined Wednesday as bank shares continued to struggle and retail sales unexpectedly fell for a second straight month. A brief reprieve after the business-inventories report and comments from President Obama fizzled.
Over the past few months I've blogged a couple of times about the public service announcement Pfizer produced in the UK to discourage guys from buying and taking counterfeit Viagra.
What does it say when a drugmaker hires a Goldman Sachs investment banker as its next Chief Financial Officer? That's the question I'm asking after Novartis announced that it's tapped a managing director of investment banking at Goldman Sachs, Jonathan Symonds, as its CFO apprentice.
Stocks pared their losses Wednesday after a report showed business inventories shrunk at a slower pace and remarks from President Obama on health-care reform. Still, stocks remained under pressure as bank shares continued to struggle and retail sales unexpectedly fell for a second straight month.
With stocks rallying for over 2 months now, dividend yields continue to fall back to Earth. The average dividend yield of the Dow 30 has fallen nearly 30% since the rally began in early March. See how the 30 companies in the Dow compare.
Comments made by Intel CEO Paul Otellini after hours could be bullish for stocks.
Stocks lost ground in afternoon trading but traded in a fairly tight range, though the Nasdaq posted losses approaching 1.5 percent.
Stocks opened slightly higher, bouncing off a rough day Monday but moving hesitantly as an economic report showed consumer weakness continues to hamper growth.
In yesterday's extension of the current rally, three more Dow stocks crossed above their 200-day moving averages. There are now seven stocks on the Dow above this technical threshold.
Against the backdrop of President Obama's healthcare reform effort, the main lobbying group for the generic drug industry says the U.S. healthcare system saved nearly three-quarters of a trillion dollars over the past ten years on generic drugs.
Cramer explains why the market stalled today and what we need to go higher.
Following are the “Fast & Furious” trades - hot ways to play Wednesday's market moving events.
Don't get so swept up in trying to predict where specific stocks are going that you ignore what they're saying about the market as a whole.
Stock action in the last week of the month supports bull position. Remember the bull position: that the great decline in stock prices, combined with government support, along with economic news that will prove to be "less bad" as the months go on, is providing a floor under the stock market.
The swine flu epidemic remains a wild card, as no one is quite certain how far the epidemic will spread.